Liron Bar-Peled, PhD

Dr. Bar-Peled studies how cancer cells adapt to stress environments, focusing on oxidative stress.  His research focuses on understanding how cells sense and respond to specific changes in their environment by activating singling pathways that lead to uncontrolled growth.  He recently studied a particular pathway in non-small cell lung cancer and identified a “druggable” protein that could be targeted with small molecules and disrupt this uncontrolled growth.

Joseph D. Schonhoft, PhD

Dr. Schonhoft [Merck Fellow] aims to understand how immune cells abnormally proliferate and secrete a pathogenic variety of antibody proteins that cause organ and tissue damage, most notably in the heart and kidneys, during diseases such as amyloidosis and within a subset of multiple myelomas. His research will explain why particular antibody molecules are toxic while others are completely benign. This information may be used to develop new diagnostic probes for the early detection of these molecules, which could greatly improve the effectiveness of current clinical treatments.

Liron Bar-Peled, PhD

Dr. Bar-Peled is exploring how the protease Caspase-8 regulates T cell activation, which represents a critical step in the adaptive immune response to cancer. While Caspase-8 has long been appreciated to be essential for T cell activation, the molecular mechanisms underlying its role in this process remain poorly understood. His work will focus on identifying and characterizing the proteins cleaved by Caspase-8, which may provide additional therapeutic avenues to activate T cells to target malignant cells in cancer patients.